Two Sigma Ventures
Venture arm incubated inside quantitative trading firm Two Sigma, backing data-driven startups and AI companies from seed through growth. In May 2026 the team spun out as independent Deviation Capital with ~$2B AUM managing the legacy TSV portfolio.
Typical check size
$1M-$10M (stage-based estimate)
Founded
2012
Headquarters
100 Avenue of the Americas, New York, NY 10013
AUM
N/A
Rounds they lead
Seed
Series A
Rounds they invest
Pre-Seed
Seed
Series A
Series B+
Portfolio companies we track
Startups in our directory that list Two Sigma Ventures as an investor (7 total).
- Aradigm Benefits platform enabling sustainable employer access to cell and gene therapies.
- Arda Therapeutics Targeted cell-depletion therapies for chronic diseases using oncology modalities outside cancer.
- Distributional AI evaluation platform measuring production ML model quality, drift, and reliability.
- Insitro ML-driven drug discovery platform applying large-scale biology data to identify novel therapeutics.
- Osmo AI-powered digital olfaction — fragrance design via molecular data and machine learning.
- Recursion Techbio company using automated labs and ML for drug discovery at scale.
- Rive Real-time interactive animation platform and runtime for apps, games, and embedded UIs.
Related investment articles
FAQs about Two Sigma Ventures
Stage fit, check size, thesis, and how founders typically approach this firm — based on public sources and our directory.
Two Sigma Ventures leads seed and Series A rounds and participates from pre-seed through growth (Series B+). Our directory reflects multi-stage coverage; the firm backs technical founders applying data and computing to novel problems.
Two Sigma Ventures does not publish a standard check-size range. Our Osmo coverage notes a $70M Series B lead in February 2026 — early-stage checks are smaller, while growth rounds can reach tens of millions.
Two Sigma Ventures is headquartered at 100 Avenue of the Americas in New York City. The team expanded to San Francisco under Deviation Capital (May 2026 spinout) and invests nationally in data- and compute-driven startups.
Two Sigma Ventures backs AI/ML and deep-tech companies where data, algorithms, and computing create defensible advantages. Our directory tags ai-ml and deep-tech. Historic bets include Recursion, Insitro, and Osmo (digital olfaction).
Two Sigma Ventures routinely leads seed, Series A, and growth rounds — our Osmo coverage notes TSV led a $70M Series B. The firm is known for high-conviction positions in technical founders.
Directory startups listing Two Sigma Ventures include Osmo, Insitro, Recursion, Rive, and Distributional — see /startup/osmo, /startup/insitro, /startup/recursion, /startup/rive, and /startup/distributional.
Review twosigma.com/ventures (and Deviation Capital's site post-spinout) for current team and thesis. Warm introductions from technical founders, academic collaborators, or co-investors are standard. Note: the team relaunched as Deviation Capital in May 2026.
See 2026-two-sigma-ventures-osmo-70m-series-b for the Osmo Series B lead and 2026-two-sigma-ventures-deviation-capital-spinout for the May 2026 spinout into Deviation Capital with ~$2B AUM.